November 7, 2024 — We have a lot to think about. Well over 3,000 people spent the better part of the week absorbing new science and insights into obesity – not to mention a momentous election. So as everyone sets about the task of catching up with routines, here is a quick take on five thoughts about what we’re […]
November 5, 2024 — This should not be so hard. New research at ObesityWeek 2024 tells us that chronic care for the chronic disease is truly compelling. Specifically, we are talking about the results of three years of treatment with tirzepatide presented yesterday from the SURMOUNT-1 study. In this study of more than a thousand adults with pre-diabetes, three […]
November 4, 2024 — From the Presidential Plenary at ObesityWeek, a primary issue standing in the way of progress is quite clear. Are we tipping toward equity in obesity care, or are we tripping over it? Tipping Toward Progress The argument for progress comes from putting the lived experience of obesity on stage to dominate the opening plenary for […]
November 3, 2024 — With the opening of ObesityWeek 2024, it’s worth stopping to consider the radically different situation for obesity medicine today in comparison to a few years ago. Obesity is becoming the new hypertension, says Lou Aronne. He called for it in 2017 and now it’s coming true. Aronne is a past president of the Obesity Society […]
November 2, 2024 — As we travel to San Antonio for ObesityWeek 2024 (OW2024) one of the principal threads we want to explore is the expanding scope of GLP-1 therapy benefits. The narrative is a moving target. We won’t have the abstracts in hand for another day. But news this week makes it clear that we have barely gotten […]
October 30, 2024 — November is upon us and thus, so is ObesityWeek 2024 in San Antonio. This has been a year of radical change in the environment for obesity research, prevention, and care. So as we peruse the program for this meeting, it comes across as a year for consolidating the understanding of this disease and transformative options […]
